Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Takeda Pharmaceutical Co ( (JP:4502) ) has provided an announcement.
Takeda and Protagonist Therapeutics presented new 52-week data from the Phase 3 VERIFY study at the ASH 2025 meeting, showing rusfertide’s sustained efficacy in controlling hematocrit levels in polycythemia vera patients. The study results reinforce rusfertide’s potential as a new standard of care, demonstrating a significant reduction in phlebotomy needs and maintaining hematocrit control, which is crucial for preventing thrombotic events and alleviating symptoms in patients.
The most recent analyst rating on (JP:4502) stock is a Hold with a Yen4898.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Co is a global pharmaceutical company based in Osaka, Japan, known for its focus on oncology, gastroenterology, neuroscience, and rare diseases. The company collaborates with Protagonist Therapeutics to develop innovative treatments, such as rusfertide, to address unmet medical needs.
YTD Price Performance: 10.28%
Average Trading Volume: 4,610,556
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen6989.7B
For detailed information about 4502 stock, go to TipRanks’ Stock Analysis page.